Amylyx Pharmaceuticals (AMLX) Receivables (2022 - 2025)

Amylyx Pharmaceuticals' Receivables history runs 4 years deep, the most recent figure standing at $188000.0 for Q4 2025.

• On a quarterly basis, Receivables fell 65.63% year-over-year to $188000.0 in Q4 2025; TTM through Dec 2025 was $188000.0, a 65.63% decrease from a year earlier, with the FY2025 full-year figure at $188000.0, down 65.63% from the prior year.
• Receivables retreated to $188000.0 in Q4 2025 per AMLX's latest filing, from $232000.0 in the prior quarter.
• Across five years, Receivables topped out at $40.6 million in Q4 2023 and bottomed at $137000.0 in Q3 2022.
• The 4-year median for Receivables is $3.0 million (2024), against an average of $11.9 million.
• Across the five-year window, Receivables soared 21398.54% in 2023 and slumped 98.65% in 2024, its largest moves.
• Year by year, Receivables stood at $15.8 million in 2022, then soared by 156.55% to $40.6 million in 2023, then slumped by 98.65% to $547000.0 in 2024, then plunged by 65.63% to $188000.0 in 2025.
• Per Business Quant, the three latest AMLX Receivables figures stand at $188000.0 (Q4 2025), $232000.0 (Q3 2025), and $203000.0 (Q2 2025).